Quality of life, treatment impact and duration, and the importance of individualized therapy are at the center of ...

An Ancillary Study of the STAMPEDE Docetaxel Trials Ruth Langley presented results from a phase 3 trial comparing transdermal estradiol to LHRH agonists for androgen suppression in M0 prostate cancer.

When prostate cancer patients need therapy to reduce male hormone levels, delivering some of the treatment via a patch on the ...

Among those with intermediate-risk prostate cancer, high PSA levels prior to HIFU led to an increased risk of overall recurrence and treatment failure. Patients with HRR-deficient metastatic ...

Recently, licensed and emerging treatments for metastatic castrate-resistant prostate cancer are transforming the prognosis for men whose disease has already progressed during or after docetaxel ...

It affects about 2% of the population and is mediated ... Alarming Rise in Rates of Advanced Prostate Cancer in California Feb. 3, 2025 — The incidence of advanced prostate cancer in California ...

A mid-stage study has uncovered an innovative approach for prostate cancer therapy through the use of transdermal estradiol patches. These patches, which deliver treatment directly through the skin, ...

If you continue to have this issue please contact [email protected]. GLP-1 receptor agonist use before pregnancy was tied to lower risks for hypertensive disorders of pregnancy and ...

it has found no evidence that GLP-1 agonist drugs such as Novo Nordisk’s Ozempic and Eli Lilly’s Trulicity can cause cancer of the thyroid. Six months ago, the Pharmacovigilance Risk ...

This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...

"The management of advanced prostate cancer has evolved significantly, driven in part by the integration of diverse biomarkers that guide treatment decisions from diagnosis through progression," says ...